VIR Stock - Vir Biotechnology, Inc.
Unlock GoAI Insights for VIR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $74.20M | $86.18M | $1.62B | $1.10B | $67.25M |
| Gross Profit | $-404,440,000 | $-486,647,000 | $994.83M | $581.54M | $67.25M |
| Gross Margin | -545.0% | -564.7% | 61.6% | 53.1% | 100.0% |
| Operating Income | $-587,165,000 | $-684,305,000 | $833.07M | $420.75M | $-296,980,000 |
| Net Income | $-521,960,000 | $-615,061,000 | $515.84M | $528.58M | $-298,665,000 |
| Net Margin | -703.4% | -713.7% | 31.9% | 48.3% | -444.1% |
| EPS | $-3.83 | $-4.59 | $3.89 | $4.07 | $-2.51 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Visit WebsiteEarnings History & Surprises
VIREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.70 | $-1.17 | -67.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.72 | $-0.80 | -11.1% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.83 | $-0.88 | -6.0% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.85 | $-0.76 | +10.6% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.96 | $-1.56 | -62.5% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.93 | $-1.02 | -9.7% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.99 | $-0.48 | +51.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-1.14 | $-0.86 | +24.6% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.21 | $-1.22 | -0.8% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.21 | $-1.45 | -19.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.81 | $-1.06 | -30.9% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.39 | $-0.76 | -92.4% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.21 | $1.30 | +719.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.17 | $-0.58 | -241.2% | ✗ MISS |
Q2 2022 | May 5, 2022 | $3.78 | $3.85 | +1.9% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $3.04 | $3.92 | +28.9% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.02 | $0.82 | +3487.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.48 | $0.46 | +195.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about VIR
What is VIR's current stock price?
What is the analyst price target for VIR?
What sector is Vir Biotechnology, Inc. in?
What is VIR's market cap?
Does VIR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VIR for comparison